Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trialBeatriz Grinsztejn, Jean‐Michel Molina, Mariza Gonçalves Morgado et al.|The Lancet Infectious Diseases|2014Cited by 98
Clinical outcomes by supplemental oxygen use in remdesivir-treated, hospitalised adults with COVID-19Nadir Arber, F. Raffi, Pallav L. Shah et al.|Infectious Diseases Now|2023Cited by 1